Swiftsure International Inc.
Holmes Biopharma Inc.: Initiates Broker Relations Program

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma Inc.: Initiates Broker Relations Program

Scottsdale, Arizona – January 23rd, 2008 – Holmes Biopharma, Inc. (Berlin
Stock Exchange symbol HHJA, WKN A0KDRX)  is pleased to announce that it has
retained the services of Newport Capital Consultants, Inc., a California
based consulting firm engaged in the provision of  broker relations
consulting expertise to private and public companies. Mr. Bryant, President
who has over 40 years of experience in the investment banking services
industry and his team of consultants are respected Associate Members of the
National Investment Bankers Association (NIBA), as well as members of the
Southern California Investment Association (SCIA). Newport Capital
Consultants has advanced over 50 companies from the OTC Board to the AMEX
and to the NYSE. Many of these companies received significant funding from
investors introduced by Newport Capital Consultants.
'The addition of Newport Capital Consultants will introduce HolmesBiopharma
to a broader network of Investment bankers through their well established
network.'
Stated John Metcalfe, President and CEO


About Holmes:

Holmes Biopharma Inc. is a contract research organization focused on
providing integrated and cost effective clinical development services to
the pharmaceutical industry and is actively involved in developing new
drugs and drug delivery systems. Currently, clinics operate in Omaha,
Nebraska USA, Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more
information about the company please visit our website at
www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe President, CEO


Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:
 
www.holmesbiopharma.com
Tel: 1-800-778-4990 Email: ir@holmesbiopharma.com
 
23.01.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------